Lung Cancer Trial, Recruiting NCT04631770 Sponsor: Tianjin Medical University Cancer Institute and Hospital Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT04631770
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • A high-resolution CT scan shows a single area of hazy, cloud-like change in the lung (called a ground-glass nodule), where the solid portion makes up half or less of the total nodule size, and there is no sign the cancer has spread to nearby lymph nodes.
  • A diagnosis of early-stage lung cancer (Stage IA, a type called non-small cell lung cancer) confirmed either before or during surgery, using standard international staging guidelines.
  • No history of any cancer in the past 5 years, and no previous lung surgery.
  • No cancer treatments of any kind received before surgery.

Who may not be able to join:

  • People who have had two separate cancers at the same time, or a second cancer diagnosed within the past 5 years.
  • People with an active bacterial or fungal infection at the time of the trial.
  • People with certain serious lung conditions, including interstitial pneumonitis (ongoing lung inflammation), pulmonary fibrosis (scarring of the lung tissue), or severe emphysema (a serious form of lung disease).
  • People currently taking steroid medications that affect the whole body (such as tablets or injections, rather than creams or inhalers).
  • People with diabetes that is not well controlled.
  • People with blood pressure that is not well controlled, or who have a history of serious heart disease or heart failure.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Zhenfa Zhenfa, MD, Tianjin Medical University Cancer Institute and Hospital

Phone: +862223340123

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Registry
ClinicalTrials.gov
Start date
1 May 2022
Est. completion
1 May 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov